Immutep Ltd (ASX: IMM) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Immutep Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $487.62 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.45 billion
Earnings per share -0.039
Dividend per share N/A
Year To Date Return -0.54%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Immutep Ltd (ASX: IMM)
    Latest News

    A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
    Share Fallers

    Why Fisher & Paykel, Immutep, Latitude, and Universal Store shares are falling

    These ASX shares are ending the week in the red...

    Read more »

    A couple are shocked and elated at the good news they've just seen on their devices.
    Share Gainers

    Why Adbri, Costa, Delta Lithium, and Immutep shares are racing higher

    These ASX shares are having a strong session despite the market volatility.

    Read more »

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Immutep, Leo Lithium, Playside, and Webjet shares are storming higher

    These ASX shares are avoiding the market weakness and storming higher.

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    Why has this ASX healthcare share exploded 50% in two days?

    The biotech company is riding high on the back of promising clinical trial data.

    Read more »

    Health workers shake hands and congratulate each other on good news.
    Healthcare Shares

    2 ASX healthcare shares smashing the All Ords today

    These healthcare shares are smashing the All Ords today...

    Read more »

    A CSL scientist looking through a telescope in a lab
    Healthcare Shares

    What's the outlook for Immutep shares in FY23?

    The biotech company continues its clinical trial momentum.

    Read more »

    Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
    Healthcare Shares

    What's the outlook for ASX biotech shares in FY23?

    ASX biotech shares could be changing course in FY23.

    Read more »

    A sad looking scientist sitting and upset about a share price fall.
    Healthcare Shares

    Why did the Immutep share price plummet 31% last month?

    June was a rough one for this ASX biotechnology stock.

    Read more »

    Two staff in a medical research laboratory wearing masks and caps work on their tests, representing the performance of ASX healthcare shares in FY22
    Healthcare Shares

    Here's how ASX healthcare shares performed in FY22

    ASX healthcare shares took a massive plunge from the restart of trade in January.

    Read more »

    Two researchers discussing results of a study with each other.
    Healthcare Shares

    Here's how ASX 200 healthcare shares performed in June

    Healthcare shares were a tad ill in June.

    Read more »

    A businessman presents a company annual report in front of a group seated at a table
    Healthcare Shares

    Own Immutep shares? Here are 3 takeaways from the company's investor update

    Investors were mute to the update.

    Read more »

    A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
    Healthcare Shares

    What's driving the Immutep share price in June?

    Can the ASX healthcare share maintain its momentum this month?

    Read more »

    Frequently Asked Questions

    No, Immutep does not pay dividends at this time.

    Immutep Ltd listed on the ASX on 23 June 1988.

    IMM ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Immutep Ltd

    Immutep Ltd (ASX: IMM) is a biotechnology company developing immunotherapy products for cancer and autoimmune diseases. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune diseases. Immutep currently has three clinical-stage candidates and two earlier-stage candidates.

    IMM Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 Dec 2024 $0.34 $-0.01 -2.94% 246,930 $0.33 $0.34 $0.33
    23 Dec 2024 $0.34 $0.00 0.00% 894,487 $0.33 $0.35 $0.33
    20 Dec 2024 $0.34 $0.00 0.00% 1,939,246 $0.35 $0.35 $0.34
    19 Dec 2024 $0.35 $-0.02 -5.56% 3,174,377 $0.35 $0.36 $0.34
    18 Dec 2024 $0.36 $0.02 5.88% 2,568,514 $0.35 $0.37 $0.35
    17 Dec 2024 $0.34 $0.00 0.00% 2,635,531 $0.35 $0.35 $0.33
    16 Dec 2024 $0.34 $-0.03 -8.22% 1,354,264 $0.36 $0.36 $0.34
    13 Dec 2024 $0.37 $-0.01 -2.67% 1,541,223 $0.37 $0.37 $0.36
    12 Dec 2024 $0.38 $0.02 5.63% 7,579,804 $0.38 $0.39 $0.36
    11 Dec 2024 $0.36 $0.02 5.88% 3,809,824 $0.34 $0.36 $0.34
    10 Dec 2024 $0.34 $0.01 2.99% 2,655,575 $0.34 $0.34 $0.33
    09 Dec 2024 $0.34 $0.01 3.03% 3,074,829 $0.33 $0.35 $0.33
    06 Dec 2024 $0.33 $0.02 6.45% 5,646,314 $0.32 $0.34 $0.31
    05 Dec 2024 $0.31 $-0.01 -3.13% 1,212,530 $0.32 $0.32 $0.31
    04 Dec 2024 $0.32 $-0.01 -3.08% 1,112,321 $0.33 $0.33 $0.32
    03 Dec 2024 $0.33 $0.01 3.13% 1,392,912 $0.31 $0.33 $0.31
    02 Dec 2024 $0.32 $-0.01 -3.08% 1,415,632 $0.32 $0.33 $0.32
    29 Nov 2024 $0.33 $0.01 3.13% 1,452,545 $0.32 $0.33 $0.32
    28 Nov 2024 $0.32 $0.01 3.23% 3,395,338 $0.32 $0.34 $0.31
    27 Nov 2024 $0.31 $0.00 0.00% 2,836,864 $0.31 $0.32 $0.30
    26 Nov 2024 $0.31 $-0.02 -6.06% 6,153,132 $0.32 $0.32 $0.31

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    06 Dec 2024 Russell Howard Exercise 304,770 $100,574
    Conversion of securities. 100,000 Director Performance Rights
    06 Dec 2024 Russell Howard Issued 304,770 $100,574
    Conversion of securities.
    06 Dec 2024 Lis (Elisabeth) Boyce Exercise 256,621 $84,684
    Conversion of securities. 333,334 Director Performance Rights
    06 Dec 2024 Lis (Elisabeth) Boyce Issued 256,621 $84,684
    Conversion of securities.
    05 Dec 2024 Marc Voigt Issued 3,600,000 $1,116,000
    Issue of securities. 7,200,000 Performance Rights
    05 Dec 2024 Frederic Triebel Issued 2,700,000 $837,000
    Issue of securities. 5,400,000 Performance Rights
    01 Oct 2024 Pete Meyers Exercise 388,889 $130,277
    Conversion of securities. 777,778 Performance Rights
    01 Oct 2024 Pete Meyers Issued 388,889 $130,277
    Conversion of securities.
    18 Sep 2024 Marc Voigt Buy 29,500 $10,030
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Russell J Howard Non-Executive ChairmanNon-Executive Director May 2013
    Dr Howard has been a Non-Executive Director of Immutep since May 8, 2013 and has been appointed as Non-Executive Chairman on November 17, 2017. He is an Australian scientist, executive manager and entrepreneur. He was a pioneer in molecular parasitology and commercialization of 'DNA Shuffling'. He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr. Howard worked at Schering-Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc. After its spin-out from GlaxoWellcome, as Maxygen's CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising US$ 260.0 million. Maxygen developed and partnered dozens of technology applications and products over 12 years of his tenure as CEO. After leaving Maxygen in 2008, he started the Cleantech company Oakbio Inc. (dba NovoNutrients) and remains involved in several innovative companies in the USA and Australia. He is a member of Risk Committee.
    Mr Pete A Meyers Non-Executive Deputy ChairmanNon-Executive Director Feb 2014
    Mr Meyers has been a Non-Executive Director of Immutep since February 12, 2014, and appointed as Non-Executive Deputy Chairman on November 17, 2017. He was the Chief Financial Officer of Slayback Pharma LLC, a KKR portfolio company, until Slayback was sold to Azurity Pharmaceuticals, Inc. in September 2023. Prior to joining Slayback Pharma LLC, Mr. Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read & Co., Credit Suisse First Boston LLC and, most recently, as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. He is Chair of the Risk Committee.
    Mr Marc Voigt Chief Financial OfficerChief Executive OfficerExecutive Director May 2012
    Mr Voigt has more than 21 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Immutep's Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurance and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments. Marc then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specializing in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectively, where he handled several licensing transactions and financing rounds.
    Professor Frederic Triebel Executive Director Sep 2022
    Prof Triebel founded Immutep S.A. in 2001 and served as its Scientific and Medical Director from 2004. He was appointed as Chief Medical Officer and Chief Scientific Officer following the acquisition of Immutep S.A. in December 2014. Prof. Triebel was appointed as a Director on September 13, 2022 and is currently Chief Scientific Officer of the Company. Before starting Immutep S.A., he was Professor in Immunology at Paris University. While working at Institute Gustave Roussy (IGR), a large cancer center in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996.
    Ms Lis (Elisabeth) Boyce Non-Executive Director Apr 2023
    Ms Boyce has been a Non-Executive Director of Immutep since April 11, 2023. Ms Boyce is a senior corporate lawyer with over 30 years of experience including capital raising, strategic collaborations, corporate governance and mergers & acquisitions. She is a partner in Piper Alderman's corporate team since January 2021, and co-chairs the firm's Life Sciences & Healthcare focus group. Prior to Piper Alderman, Lis has held various leadership roles at Dentons and DibbsBarker. Lis' strong focus on Life Sciences is reflected in her appointment as deputy chair of AusBiotech's AusMedtech Advisory Group, and as Chair of AusBiotech's Leadership Committee for NSW. She is member of Risk COmmittee.
    Ms Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
    -
    Ms Indira Naidu Joint Company Secretary Jan 2021
    -
    Dr Florian Vogl Chief Medical Officer
    -
    Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
    -
    Indira Naidu Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 392,524,418 27.02%
    J P Morgan Nominees Australia Pty Limited 163,987,746 11.29%
    National Nominees Limited 124,855,746 8.60%
    UBS Nominees Pty Ltd 100,644,056 6.93%
    Citicorp Nominees Pty Limited 99,805,429 6.87%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 16,565,303 1.14%
    BNP Paribas Noms Pty Ltd 14,012,760 0.96%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 14,011,919 0.96%
    BNP Paribas Nominees Pty Ltd <Clearstream> 13,521,174 0.93%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 13,077,206 0.90%
    Marc Voigt 11,191,695 0.77%
    Netwealth Investments Limited <Wrap Services A/C> 9,854,513 0.68%
    Frederic Triebel 8,653,764 0.60%
    BNP Paribas Noms (Nz) Ltd 7,253,493 0.50%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 6,001,564 0.41%
    HSBC Custody Nominees (Australia) Limited-GSI EDA 5,921,052 0.41%
    Bnp Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 5,713,856 0.39%
    HB Biotechnology Ltd 4,962,791 0.34%
    UBS Nominees Pty Ltd i 4,545,454 0.31%
    Macenrock Pty Ltd <Macenrock S/F A/C> 4,114,620 0.28%

    Profile

    since

    Note